SCHEDULE: BlackRock Amends Stake in Revolution Medicines to 4.5%
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, disclosing a beneficial ownership of 4.5% of Revolution Medicines Inc.'s common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 8,399,214 shares of Revolution Medicines Inc. common stock.
- This represents 4.5% of the total outstanding common stock of Revolution Medicines Inc.
- BlackRock, Inc. holds sole voting power over 8,100,605 shares and sole dispositive power over 8,399,214 shares.
- No shared voting or dispositive power was reported by BlackRock, Inc.
- The filing confirms that BlackRock's aggregate interest is less than 5% of the class, consistent with a Schedule 13G filing.
- No single person's interest within BlackRock's reported holdings is more than five percent of Revolution Medicines Inc.'s total outstanding common shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing an institutional ownership stake, providing no direct positive or negative sentiment regarding the issuer's operational or financial performance. The 4.5% stake is below the 5% threshold for active influence.
Positives
- BlackRock, a prominent institutional investor, maintains a significant stake in Revolution Medicines Inc., which may signal continued institutional confidence in the company.
Future Outlook
NA
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing is a routine disclosure of an institutional investor's passive stake in a publicly traded company, common practice within the financial industry for transparency regarding significant, but non-controlling, ownership positions.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership in Revolution Medicines Inc.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previously revoked Power of Attorney. |
| 01/21/2025 | Execution date of the current Power of Attorney for BlackRock, Inc. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 07/17/2025 | Date of Schedule 13G Amendment No. 4 filing. |
Keywords
Revolution Medicines Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.